Comparative Pharmacology
Head-to-head clinical analysis: BRINSUPRI versus CAPTOPRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRINSUPRI versus CAPTOPRIL.
BRINSUPRI vs CAPTOPRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRINSUPRI is a novel oral cyclin-dependent kinase (CDK) inhibitor that selectively inhibits CDK4 and CDK6, thereby blocking phosphorylation of the retinoblastoma (Rb) protein and preventing G1-to-S phase cell cycle progression. This induces cell cycle arrest in cancer cells with intact Rb function.
Competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion.
4 mg orally once daily, with or without food.
Initial: 25 mg PO 2-3 times daily; target dose: 50 mg PO 2-3 times daily; maximum: 450 mg/day. For heart failure: start 6.25-12.5 mg PO 3 times daily, titrate to 25-50 mg PO 3 times daily.
None Documented
None Documented
Clinical Note
moderateCaptopril + Benzydamine
"The risk or severity of adverse effects can be increased when Captopril is combined with Benzydamine."
Clinical Note
moderateCaptopril + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Captopril."
Clinical Note
moderateCaptopril + Droxicam
"The risk or severity of adverse effects can be increased when Captopril is combined with Droxicam."
Clinical Note
moderateCaptopril + Loxoprofen
Terminal elimination half-life is approximately 20-30 hours in healthy adults, allowing once-daily dosing. In renal impairment (CrCl <30 mL/min), half-life may extend to >50 hours, requiring dose adjustment.
Terminal half-life 1.9 hours, prolonged to 3.5-32 hours in renal impairment; clinical context: requires adjusted dosing in renal failure
Primarily renal excretion as unchanged drug (70-85%) and minor fecal elimination (10-15%). Biliary excretion accounts for <5%.
Primarily renal (50-60% unchanged), with minor biliary/fecal elimination (<5%)
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor
"The risk or severity of adverse effects can be increased when Captopril is combined with Loxoprofen."